Total Payments
$486,380
2021 Payments
$2,890
Companies
8
Transactions
80
Payment Breakdown by Category
Research$457,160 (94.0%)
Consulting$20,825 (4.3%)
Travel$4,114 (0.8%)
Other$2,890 (0.6%)
Food & Beverage$1,391 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $457,160 | 36 | 94.0% |
| Consulting Fee | $20,825 | 3 | 4.3% |
| Travel and Lodging | $4,114 | 18 | 0.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,890 | 3 | 0.6% |
| Food and Beverage | $1,391 | 20 | 0.3% |
Payments by Type
Research
$457,160
36 transactions
General
$29,220
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sebela Pharmaceuticals Inc. | $346,293 | 33 | $0 (2020) |
| Exeltis, USA Inc. | $106,820 | 1 | $0 (2020) |
| TherapeuticsMD, Inc. | $16,125 | 1 | $0 (2020) |
| MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | $5,669 | 14 | $0 (2020) |
| Allergan Inc. | $4,047 | 2 | $0 (2017) |
| Lupin Inc. | $3,150 | 8 | $0 (2018) |
| Agile Therapeutics, Inc. | $2,890 | 3 | $0 (2021) |
| Ferring International Pharmascience Center US | $1,386 | 18 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $2,890 | 3 | Agile Therapeutics, Inc. ($2,890) |
| 2020 | $253,655 | 25 | Sebela Pharmaceuticals Inc. ($127,209) |
| 2019 | $219,084 | 11 | Sebela Pharmaceuticals Inc. ($219,084) |
| 2018 | $3,150 | 8 | Lupin Inc. ($3,150) |
| 2017 | $7,602 | 33 | Allergan Inc. ($4,047) |
All Payment Transactions
80 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/24/2021 | Agile Therapeutics, Inc. | Twirla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Birth Control Contraceptive Patch | ||||||
| 04/23/2021 | Agile Therapeutics, Inc. | Twirla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Birth Control Contraceptive Patch | ||||||
| 02/01/2021 | Agile Therapeutics, Inc. | Twirla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,540.00 | General |
| Category: Birth Control Contraceptive Patch | ||||||
| 12/31/2020 | Exeltis, USA Inc. | LPRI-424 (Drug) | — | Cash or cash equivalent | $106,820.34 | Research |
| Study: A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles • Category: Oral Contraceptive | ||||||
| 11/13/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $7,460.35 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 10/16/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $10,374.00 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 10/16/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,620.40 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 10/16/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 10/16/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $465.25 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 09/29/2020 | MITSUBISHI TANABE PHARMA DEVELOPMENT AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| 09/18/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $9,966.45 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 08/21/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $13,207.85 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 07/30/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $2,962.50 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 07/30/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,031.25 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 07/14/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $12,554.25 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 06/18/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $9,183.65 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $5,776.00 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $631.25 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $615.00 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $475.00 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $373.25 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $341.65 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/28/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $220.00 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 05/14/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $7,246.60 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
| 04/23/2020 | Sebela Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $13,340.85 | Research |
| Study: A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability | Sebela Pharmaceuticals Inc. | $219,084 | 11 |
| A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAUTERINE CONTRACEPTIVE FOR CONTRACEPTIVE EFFICACY, SAFETY, AND TOLERABILITY | Sebela Pharmaceuticals Inc. | $127,209 | 22 |
| A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability ofLPRI-424, 13 Cycles | Exeltis, USA Inc. | $106,820 | 1 |
| A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ULIPRISTAL ACETATE FOR THE INTERMITTENT TREATMENT OF ABNORMAL UTERINE BLEEDING ASSOCIATED WITH LEIOMYOMAS | Allergan Inc. | $4,047 | 2 |
About Dr. Arthur Waldbaum, MD
Dr. Arthur Waldbaum, MD is a Gynecology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386743441.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arthur Waldbaum, MD has received a total of $486,380 in payments from pharmaceutical and medical device companies, with $2,890 received in 2021. These payments were reported across 80 transactions from 8 companies. The most common payment nature is "" ($457,160).
Ad
Practice Information
- Specialty Gynecology
- Location Denver, CO
- Active Since 09/22/2006
- Last Updated 08/09/2010
- Taxonomy Code 207VG0400X
- Entity Type Individual
- NPI Number 1386743441
Products in Payments
- LPRI-424 (Drug) $106,820
- SOLOSEC (Drug) $3,150
- Twirla (Drug) $2,890
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecology Doctors in Denver
Dr. Mandi Beman, M.d, M.D
Gynecology — Payments: $36,292
Gynecology $36,292
Dr. Kristinell Keil, Md, MD
Gynecology — Payments: $20,038
Gynecology $20,038
Dr. Michael Moore, M.d, M.D
Gynecology — Payments: $10,185
Gynecology $10,185
Paula Vasichko
Gynecology — Payments: $4,667
Gynecology $4,667
Katherine Dugan, Md, MD
Gynecology — Payments: $1,454
Gynecology $1,454
Dr. Jennifer Onstad, M.d, M.D
Gynecology — Payments: $1,075
Gynecology $1,075